利托那韦-话题@MedSci

#利托那韦#

38篇内容 | 872人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1566169, encodeId=598415661699c, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, objectType=article, longId=301548, objectId=87a330154822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87a330154822, replyNumber=0, likeNumber=48, createdTime=2022-03-25, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87a330154822, moduleTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87a330154822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560160, encodeId=69d315601600b, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, objectType=article, longId=301548, objectId=87a330154822, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87a330154822, replyNumber=0, likeNumber=54, createdTime=2022-03-25, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87a330154822, moduleTitle=关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87a330154822)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560159, encodeId=aa02156015939, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果, objectType=article, longId=217663, objectId=a15321e66354, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a15321e66354, replyNumber=0, likeNumber=66, createdTime=2021-09-27, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a15321e66354, moduleTitle=CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a15321e66354)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566168, encodeId=f795156616833, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果, objectType=article, longId=217663, objectId=a15321e66354, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a15321e66354, replyNumber=0, likeNumber=49, createdTime=2021-09-27, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a15321e66354, moduleTitle=CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a15321e66354)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566167, encodeId=bef7156616e20, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响, objectType=article, longId=216789, objectId=23a8216e89a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23a8216e89a0, replyNumber=0, likeNumber=41, createdTime=2021-09-09, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23a8216e89a0, moduleTitle=JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23a8216e89a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560158, encodeId=1a7b156015866, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响, objectType=article, longId=216789, objectId=23a8216e89a0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23a8216e89a0, replyNumber=0, likeNumber=40, createdTime=2021-09-09, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23a8216e89a0, moduleTitle=JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23a8216e89a0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566166, encodeId=8e921566166b8, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败, objectType=article, longId=202496, objectId=b1c420249608, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1c420249608, replyNumber=0, likeNumber=50, createdTime=2020-10-27, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1c420249608, moduleTitle=Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1c420249608)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560157, encodeId=7916156015e58, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败, objectType=article, longId=202496, objectId=b1c420249608, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1c420249608, replyNumber=0, likeNumber=34, createdTime=2020-10-27, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1c420249608, moduleTitle=Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1c420249608)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560156, encodeId=b0781560156db, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, objectType=article, longId=201940, objectId=9263201940fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9263201940fd, replyNumber=0, likeNumber=45, createdTime=2020-10-12, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9263201940fd, moduleTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9263201940fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566165, encodeId=cd801566165de, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, objectType=article, longId=201940, objectId=9263201940fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9263201940fd, replyNumber=0, likeNumber=34, createdTime=2020-10-12, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9263201940fd, moduleTitle=NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9263201940fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560155, encodeId=3f29156015578, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, objectType=article, longId=197416, objectId=429719e4161f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=429719e4161f, replyNumber=0, likeNumber=37, createdTime=2020-07-14, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=429719e4161f, moduleTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=429719e4161f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566164, encodeId=c1a215661646a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, objectType=article, longId=197416, objectId=429719e4161f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=429719e4161f, replyNumber=0, likeNumber=37, createdTime=2020-07-14, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=429719e4161f, moduleTitle=危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=429719e4161f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560154, encodeId=f79c156015437, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验, objectType=article, longId=197114, objectId=49ec19e114d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ec19e114d3, replyNumber=0, likeNumber=38, createdTime=2020-07-07, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ec19e114d3, moduleTitle=世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ec19e114d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566163, encodeId=1742156616319, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验, objectType=article, longId=197114, objectId=49ec19e114d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=49ec19e114d3, replyNumber=0, likeNumber=0, createdTime=2020-07-07, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=49ec19e114d3, moduleTitle=世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=49ec19e114d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560153, encodeId=5d3a156015312, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, objectType=article, longId=193897, objectId=c69119389efc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69119389efc, replyNumber=0, likeNumber=46, createdTime=2020-05-12, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69119389efc, moduleTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69119389efc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566162, encodeId=4b1115661624e, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, objectType=article, longId=193897, objectId=c69119389efc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c69119389efc, replyNumber=0, likeNumber=38, createdTime=2020-05-12, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c69119389efc, moduleTitle=Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c69119389efc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560152, encodeId=86c71560152df, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果, objectType=article, longId=190405, objectId=98931904052a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98931904052a, replyNumber=0, likeNumber=47, createdTime=2020-03-21, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98931904052a, moduleTitle=NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98931904052a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566161, encodeId=24c51566161d7, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果, objectType=article, longId=190405, objectId=98931904052a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=98931904052a, replyNumber=0, likeNumber=40, createdTime=2020-03-21, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=98931904052a, moduleTitle=NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=98931904052a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1560151, encodeId=acd015601518a, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果, objectType=article, longId=190344, objectId=9a5d190344f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a5d190344f0, replyNumber=0, likeNumber=34, createdTime=2020-03-20, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a5d190344f0, moduleTitle=NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a5d190344f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1566160, encodeId=612d1566160d0, content=<a href='/topic/show?id=ecf3323007c' target=_blank style='color:#2F92EE;'>#利托那韦#</a>, objectTitle=NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果, objectType=article, longId=190344, objectId=9a5d190344f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a5d190344f0, replyNumber=0, likeNumber=42, createdTime=2020-03-20, rootId=0, userName=sunyl12, userId=e46815077905, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a5d190344f0, moduleTitle=NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a5d190344f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

利托那韦

2020-05-29

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知

2022-03-25

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

关于调整抗新型冠状病毒药物PF-07321332/利托那韦片（Paxlovid）适应症等内容的通知

2022-03-25

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果

2021-09-27

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

CID：奈韦拉平与洛匹那韦/利托那韦在HIV感染婴幼儿的抗逆转录病毒治疗效果

2021-09-27

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响

2021-09-09

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

JAMA:羟氯喹或洛匹那韦利托那韦早期治疗对新型冠状病毒肺炎住院风险的影响

2021-09-09

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败

2020-10-27

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet：洛匹那韦-利托那韦用于新冠肺炎临床试验失败

2020-10-27

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征

2020-10-12

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：重组干扰素β-1b、洛匹那韦和利托那韦联合治疗中东呼吸综合征

2020-10-12

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高

2020-07-14

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

危重COVID-19患者经洛匹那韦和利托那韦联合治疗时：心动过缓风险较高

2020-07-14

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验

2020-07-07

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

世卫组织停止羟氯喹、洛匹那韦/利托那韦分支试验

2020-07-07

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效

2020-05-12

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

Lancet:干扰素β-1b、洛匹那韦、利托那韦和利巴韦林治疗轻中度新冠肺炎有效

2020-05-12

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果

2020-03-21

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：洛匹那韦-利托那韦治疗重症COVID-19未显示出确切效果

2020-03-21

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果

2020-03-20

sunyl12 (审核中...)

前往app查看评论内容

#利托那韦#

NEJM：曹彬团队公布洛匹那韦-利托那韦治疗新冠临床结果

2020-03-20

科室
- - 订阅+
  - 更多科室
工具
服务